Psych · Child and adolescent psychiatry — neurodevelopmental
ADHD across the lifespan
Also known as Attention-deficit/hyperactivity disorder · Attention deficit hyperactivity disorder · ADHD · Adult ADHD · Hyperkinetic disorder · ADD · Attention deficit disorder
Exam-exhaustive fellowship reference on ADHD from childhood through adulthood — DSM-5-TR and ICD-11 criteria; multi-informant assessment; differentials; MTA and Cortese NMA evidence; stimulant and non-stimulant doses with monitoring; CBT/coaching; substance misuse and driving risk. FRANZCP-primary, globally tagged.
Practise this topic
On this page
Study tools
Your progress
Saved on this device.
Target exams
Red flags
- Suicidal ideation or self-harm with comorbid depression/anxiety — full risk assessment and safety plan; do not attribute everything to ADHD alone
- Cardiac history, unexplained syncope, or family sudden cardiac death — baseline review and ECG as indicated before stimulants or atomoxetine
- Active substance use disorder with diversion risk — prefer supervised long-acting formulations or non-stimulants; treat SUD in parallel
- New manic or psychotic symptoms after stimulant initiation — stop agent, reassess bipolar spectrum and substances
- Significant growth faltering on stimulants — plot height/weight; consider dose timing, holidays, or switch
- High-risk driving with untreated severe ADHD — counsel, document, and intensify treatment; reporting duties are jurisdiction-specific
Meet the patient
A 28-year-old software tester arrives with a printed list. Three jobs in four years, two lost to missed deadlines rather than bad code. Bills late despite money in the account. Two SSRI trials for "anxiety" that did nothing. Her partner says she hyperfocuses for nine hours, then cannot start the dishwasher.[4][18]
She has no school reports and her mother has died. The examiner's question is never "does she have ADHD". It is "how will you decide, without the paperwork everyone told you was essential?" That question is this whole topic.[18][19]
References19ShowHide
- [1]The MTA Cooperative Group A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD Arch Gen Psychiatry, 1999.PMID 10591283
- [2]Molina BSG, Hinshaw SP, Swanson JM, Arnold LE, et al. The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study J Am Acad Child Adolesc Psychiatry, 2009.PMID 19318991
- [3]Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis Lancet Psychiatry, 2018.PMID 30097390
- [4]Kessler RC, Adler L, Barkley R, Biederman J, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication Am J Psychiatry, 2006.PMID 16585449
- [5]Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA The worldwide prevalence of ADHD: a systematic review and metaregression analysis Am J Psychiatry, 2007.PMID 17541055
- [6]Simon V, Czobor P, Bálint S, Mészáros A, Bitter I Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis Br J Psychiatry, 2009.PMID 19252145
- [7]Faraone SV, Perlis RH, Doyle AE, Smoller JW, et al. Molecular genetics of attention-deficit/hyperactivity disorder Biol Psychiatry, 2005.PMID 15950004
- [8]Willcutt EG, Doyle AE, Nigg JT, Faraone SV, Pennington BF Validity of the executive function theory of attention-deficit/hyperactivity disorder: a meta-analytic review Biol Psychiatry, 2005.PMID 15950006
- [9]Michelson D, Allen AJ, Busner J, Casat C, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study Am J Psychiatry, 2002.PMID 12411225
- [10]Sallee FR, McGough J, Wigal T, Donahue J, et al. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial J Am Acad Child Adolesc Psychiatry, 2009.PMID 19106767
- [11]Safren SA, Sprich S, Mimiaga MJ, Surman C, et al. Cognitive behavioral therapy vs relaxation with educational support for medication-treated adults with ADHD and persistent symptoms: a randomized controlled trial JAMA, 2010.PMID 20736471
- [12]Wilens TE Attention deficit hyperactivity disorder and substance use disorders Am J Psychiatry, 2006.PMID 17151154
- [13]Lichtenstein P, Halldner L, Zetterqvist J, Sjölander A, et al. Medication for attention deficit-hyperactivity disorder and criminality N Engl J Med, 2012.PMID 23171097
- [14]Cooper WO, Habel LA, Sox CM, Chan KA, et al. ADHD drugs and serious cardiovascular events in children and young adults N Engl J Med, 2011.PMID 22043968
- [15]Vaa T ADHD and relative risk of accidents in road traffic: a meta-analysis Accid Anal Prev, 2014.PMID 24238842
- [16]Jerome L, Habinski L, Segal A Attention-deficit/hyperactivity disorder (ADHD) and driving risk: a review of the literature and a methodological critique Curr Psychiatry Rep, 2006.PMID 16968625
- [17]Pliszka S; AACAP Work Group on Quality Issues Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder J Am Acad Child Adolesc Psychiatry, 2007.PMID 17581453
- [18]Kooij SJ, Bejerot S, Blackwell A, Caci H, et al. European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD BMC Psychiatry, 2010.PMID 20815868
- [19]Kooij JJS, Bijlenga D, Salerno L, Jaeschke R, et al. Updated European Consensus Statement on diagnosis and treatment of adult ADHD Eur Psychiatry, 2019.PMID 30453134